Stock 0512 CHINA GRAND PHA.AND HEALTHCARE HLD. LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

China Grand Pha.and Healthcare Hld. Ltd. Stock Hong Kong S.E.

Equities

0512

BMG210A71198

Pharmaceuticals

Financials

Sales 2024 * 11.95B 1.53B 2.09B Sales 2025 * 13.58B 1.74B 2.38B Capitalization 16.28B 2.09B 2.85B
Net income 2024 * 2.23B 285M 391M Net income 2025 * 2.54B 325M 445M EV / Sales 2024 * 1.36 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.2 x
P/E ratio 2024 *
7.38 x
P/E ratio 2025 *
6.46 x
Employees -
Yield 2024 *
6.67%
Yield 2025 *
6.24%
Free-Float 28.38%
More Fundamentals * Assessed data

Chart China Grand Pha.and Healthcare Hld. Ltd.

Dynamic Chart

Latest news about China Grand Pha.and Healthcare Hld. Ltd.

Grand Pharmaceutical Group Limited Announces Executive Changes CI
Grand Pharmaceutical Group Enrolls First Patient in Phase 1 Study for Myopia Eye Drops in China MT
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment CI
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump MT
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication MT
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial MT
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China MT
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops MT
More news

Press releases China Grand Pha.and Healthcare Hld. Ltd.

China Monthly Antitrust Update - June 2023 AQ
Telix-Grand Pharma Investor Webcast AQ
VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC PATIENT OF THE U.S. CLINICAL TRIAL PU
China Grand Pharmaceutical and Healthcare : Proxy form for the annual general meeting to be held on 1 June 2021 or any adjournment thereof PU
China Grand Pharmaceutical and Healthcare : GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING PU
More press releases

Managers and Directors - China Grand Pha.and Healthcare Hld. Ltd.

Managers TitleAgeSince
Chao Zhou CEO
 Chief Executive Officer 34 19-03-31
Tin Chung Foo SEC
 Corporate Secretary 56 11-08-31
Members of the board TitleAgeSince
Tosi Wan So BRD
 Director/Board Member 61 05-03-20
Ye Bi Hu BRD
 Director/Board Member 60 18-12-30
Geng Pei BRD
 Director/Board Member 64 11-05-11
More insiders

Company Profile

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
Sector
Pharmaceuticals
Calendar
2024-08-06 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.09% 819B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.93% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.28% 329B
ABBVIE INC. Stock AbbVie Inc.
+9.60% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 225B
NOVARTIS AG Stock Novartis AG
+13.31% 217B
AMGEN INC. Stock Amgen Inc.
+8.03% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 158B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 512 Stock
  4. 0512 Stock